Diana Gimenez

Diana Gimenez

Auto-generated profile, based on publicly available information

Diana Gimenez

School of Chemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
DGDiana Gimenez
Diana Gimenez
APAoife Phelan
Aoife Phelan
Cormac MurphyCormac Murphy
Cormac Murphy
Steven CobbSteven Cobb
Steven Cobb
We previously reviewed the use of 19F NMR in the broad field of chemical biology [Cobb, S. L.; Murphy, C. D. J. Fluorine Chem. 2009, 130, 132–140] and present here a summary of the literature from the last decade that has the technique as the central method of analysis. The topics covered include the synthesis of new fluorinated probes and their incorporation into macromolecules, the application of 19F NMR to monitor protein–protein interactions, protein–ligand interactions, physiologically relevant ions and in the structural analysis of proteins and nucleic acids. The continued relevance of the technique to investigate biosynthesis and biodegradation of fluorinated organic compounds is also described.

28 November 2024 in Chemical Science
Verified
Journal Article
Open access
PDF file
DGDiana Gimenez
Diana Gimenez
MWMartin Walko
Martin Walko
JMJennifer A. Miles
Jennifer A. Miles
RBRichard Bayliss
Richard Bayliss
MWMegan H. Wright
Megan H. Wright
AWAndrew J. Wilson
Andrew J. Wilson
Peptidomimetic design for non-canonical interfaces is less well established than for α-helix and β-strand mediated protein–protein interactions. Using the TACC3/Aurora-A kinase interaction as a model, we developed a series of constrained TACC3 peptide variants with 10-fold increased binding potencies (Kd) towards Aurora-A in comparison to the parent peptide. High-affinity is achieved in part by restricting the accessible conformational ensemble of the peptide leading to a more favourable entropy of binding. In addition to acting as potent orthosteric TACC3/Aurora-A inhibitors, these peptidomimetics were shown to activate the kinase and inhibit the N-Myc/Aurora-A interaction at a distal site. Thus, the potency of these tools uniquely allowed us to unveil new insight into the role of allosteric communication in the kinase.

9 September 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
DGDiana Gimenez
Diana Gimenez
MWMartin Walko
Martin Walko
JMJennifer Miles
Jennifer Miles
MWMegan Wright
Megan Wright
RBRichard Bayliss
Richard Bayliss
WAWilson Andrew
Wilson Andrew
Peptidomimetic design for non-canonical interfaces is less well established than for α-helix and β-strand mediated protein-protein interactions. Using the TACC3/Aurora-A kinase interaction as a model, we developed a series of constrained TACC3 peptide variants with 10-fold increased binding potencies (Kd) towards Aurora-A in comparison to the parent peptide. High-affinity is achieved in part by restricting the accessible conformational ensemble of the peptide leading to a more favourable entropy of binding. In addition to acting as potent orthosteric TACC3/Aurora-A inhibitors, these peptidomimetics were shown to activate the kinase and inhibit the N-Myc/Aurora-A interaction at a distal site. Thus, the potency of these tools uniquely allowed us to unveil new insight into the role of allosteric communication in the kinase.

19 September 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
RDRobert Dawber
Robert Dawber
DGDiana Gimenez
Diana Gimenez
MBMatthew Batchelor
Matthew Batchelor
JMJennifer Miles
Jennifer Miles
MWMegan Wright
Megan Wright
WAWilson Andrew
Wilson Andrew
Using N-Myc61-89 as a starting template we showcase the systematic use of truncation and maleimide constraining to develop peptidomimetic inhibitors of the N-Myc/Aurora-A protein–protein interaction (PPI); a potential anticancer drug discovery target. The most promising of these – N-Myc61-89-E80C/E84C-mal – a relatively small ligand efficient peptide, is shown to favour a more Aurora-A compliant binding ensemble in comparison to the linear wild-type sequence as observed through fluorescence anisotropy competition assays, circular dichroism (CD) and nuclear magnetic resonance (NMR) experiments. Further in silico investigation of this peptide in its Aurora-A bound state, by molecular dynamics (MD) simulations, imply (i) the bound conformation is more stable as a consequence of the constraint, which likely suppresses dissociation and (ii) the constraint may make further stabilizing interactions with the Aurora-A surface. Taken together this work unveils the first orthosteric N-Myc/Aurora-A inhibitor and provides useful insights on the biophysical properties and thus design of constrained peptides, an attractive therapeutic modality.